Drug reference
pembrolizumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks interaction between PD-1 and its ligands, PD-L1 and PD-L2
Common side effects
- Anemia
- Fatigue
- Increased AST
- Lymphopenia
- Hyperglycemia
- Hypertriglyceridemia
- Hyponatremia
Related conditions
Frequently asked questions
What drug class is pembrolizumab?
pembrolizumab belongs to: Oncology.
How does pembrolizumab work?
Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks interaction between PD-1 and its ligands, PD-L1 and PD-L2
What are the common side effects of pembrolizumab?
Anemia, Fatigue, Increased AST, Lymphopenia, Hyperglycemia, Hypertriglyceridemia, Hyponatremia
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.